Enobosarm

MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced multiple presentations at The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) 18th International Conference, and the SCWD’s Regulatory and Clinical Trials Update Regulatory Workshop, both in Rome, Italy. 18th International Conference of the Society on Sarcopenia, Cachexia, and Wasting Disorders Program Session P: Weight loss drugs and cardiovascular healthPresenter: Mitchell Steiner, Veru Inc.’s Chairman, President & CEOSession Date: December 12, 2025Presentation Number: P3Presentation Name: The Veru ExperiencePresentation Time: 4:30 pm – 4:45 pm Central European TimePresentation Location: Hall A, A. Roma Lifestyle Hotel, Rome, Italy Program Session U: THERAPEUTICS, Novel strategies to address sarcopenia while treating obesity - round table discussionPresenter: Mitchell Steiner, Veru Inc.’s Chairman, President & CEO Session Date: December 13, 2025Presentation Number: U3Presentation Name: EnobosarmPresentation Time: 10:00 am - 10:15 am Central European TimePresentation Location: Hall A, A. Roma Lifestyle Hotel, Rome, Italy Additional information on the meeting can be found on the following website: https://society-scwd.org/annual-conference/ SCWD Regulatory and Clinical Trials Update - Regulatory Workshop Presentation Name: Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory IssuesTherapeutic approaches to prevent/counteract skeletal muscle loss during incretin therapy – drugs, trial designs, and endpoints. Comments from industry representatives: Lilly approachVeru approach: Mitchell Steiner, Veru Inc.’s Chairman, President & CEOActimed approachRegeneron approach Academic discussants Regulatory considerations: EMA+FDA representativesGeneral discussionSession Date: December 11, 2025Session Number: C2Session Time: 10:15 am - 11:15 am Central European TimeSession Location: A.Roma Lifestyle Hotel, Rome, Italy Presentation Name: Possible Endpoints for Regulatory Approval of Treatments Addressing Muscle Wasting in the Context of Obesity Therapy Reviewing possible endpointsIndustry viewpoint: Mitchell Steiner, Veru Inc.’s Chairman, President & CEORegulatory considerationsGeneral discussion Session Date: December 11, 2025Session Number: C3Session Time: 11:15 am - 11:55 am Central European TimeSession Location: A.Roma Lifestyle Hotel, Rome, Italy About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass leading to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. Enobosarm Obesity Program - Enobosarm is a next generation drug that makes weight reduction by GLP-1 RA more tissue selective for fat loss – Phase 2b QUALITY clinical studyThe Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction. After completing the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial ended at 16 weeks, participants continued into a Phase 2b maintenance extension study where all patients discontinued semaglutide treatment, but continued receiving placebo, enobosarm 3mg, or enobosarm 6mg as monotherapy in a double-blind fashion for 12 weeks. The Phase 2b QUALITY and Maintenance Extension clinical trial was a positive study that demonstrated that preserving lean mass and physical function with enobosarm plus semaglutide led to greater fat loss during the 16 week active weight loss period. While weight loss was similar across treatment groups in this short 16 week study, we anticipate that preservation of lean mass and function will lead to increased energy expenditure, and this effect coupled with the direct effects of enobosarm on the additional selective reduction in fat mass will result in incremental weight reduction in a longer clinical study in patients who have obesity. Planned Phase 2b PLATEAU clinical studyVeru’s planned Phase 2b PLATEAU clinical study will evaluate the effect of enobosarm 3mg on total body weight, physical function, and safety in approximately 200 patients who have obesity (BMI ≥ 35) and are initiating GLP-1 RA treatment for weight reduction. The primary efficacy endpoint of the study is the percent change from baseline in total body weight at 72 weeks. An interim analysis will be conducted at 36 weeks to assess the percent change from baseline in lean body mass and fat mass, as measured by DEXA scans. The key secondary endpoints are total fat mass, total lean mass, physical function (stair climb test), bone mineral density, and patient reported outcome questionnaires for physical function (SF-36 PF-10, and IWQOL-lite CT physical function). The Phase 2b PLATEAU clinical study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau observed in patients with obesity receiving GLP-1 RA treatment to achieve clinically meaningful incremental weight reduction and preserve muscle mass and physical function by 72 weeks. The clinical study is expected to begin in calendar Q1 2026. Forward-Looking StatementsThis press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to the planned design, enrollment, timing, commencement, interim and full data readout timing, scope and regulatory pathways for the continued development of enobosarm in patients with obesity, including the planned PLATEAU Phase 2b study; whether clinically meaningful incremental weight loss in the PLATEAU Phase 2b study will continue to be seen as an acceptable primary endpoint by the FDA to support potential approval; whether the FDA will continue to accept 3mg as an acceptable dosage for enobosarm in the planned PLATEAU Phase 2b study or in any other studies; whether the FDA will further evolve its position on the acceptable patient population for the PLATEAU Phase 2b study or any other future studies; whether the Company will be able to partner with any other company in the development of enobosarm; whether the results of the Phase 2b QUALITY study and the extension maintenance study of enobosarm, including weight loss, preservation of lean mass and function, will be replicated to the same or any degree in the planned PLATEAU Phase 2b study or in any future Phase 3 studies; whether patients treated with enobosarm in the planned PLATEAU Phase 2B study will exhibit increased energy and whether such effects will result in incremental weight reduction; the expected costs, timing, patient population, design, endpoints and results of the planned PLATEAU Phase 2b study or any future Phase 3 studies of enobosarm in patients with obesity; whether the Company will be able to raise sufficient capital, dilutive or otherwise, to fund the PLATEAU Phase 2b study of enobosarm in patients with obesity or any other studies; whether the Company will be able to recruit a sufficient number of patients in a timely manner for the PLATEAU Phase 2b study; whether the Company will be able to obtain sufficient GLP-1 RA drugs in a timely or cost-effective manner in the planned PLATEAU Phase 2b study or any future Phase 3 studies; whether the Company will be able to engage clinical research organizations and recruit patients for the PLATEAU Phase 2b program and in a timely or cost-effective manner; whether enobosarm will cause weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will cause weight loss in the planned PLATEAU Phase 2b study or any future Phase 3 studies or, if approved and commercialized, in clinical practice; whether patients treated with enobosarm for a longer period of time than in the Phase 2b QUALITY study will experience weight loss or have a greater loss of adiposity or greater weight loss than with GLP-1 RA drug alone; whether and when enobosarm will be approved by the FDA as a weight loss drug or a body composition drug or any other type of drug; and whether and when the Company will be able to further advance the development of sabizabulin in atherosclerotic disease. The words "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments, or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the Company’s ability to reach agreement with FDA on study design requirements for the Company’s planned clinical studies, including for the Phase 2b program for enobosarm as a weight loss or body composition drug and the number of future Phase 3 studies to be required and the cost thereof; potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects in clinical studies or an inability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development as well as other operations of the Company; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the potential for disruptions at the FDA or other government agencies to negatively affect our business, including as a result of a future shutdown of the U.S. government; any products of the Company, if approved, possibly not being commercially successful; the ability of the Company to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable us to continue as a going concern; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; the Company’s ability to protect and enforce its intellectual property; costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation and litigation with the purchaser of the Company’s FC2 business; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2024, and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors. Wegovy® is a registered trademark of Novo Nordisk A/S. Investor and Media Contact:Samuel FischExecutive Director, Investor Relations and Corporate CommunicationsEmail: veruinvestor@verupharma.com

2025年肥胖症周大会于11月4日至7日在亚特兰大举办，会上公布的临床数据具有开创性意义，标志着肥胖症治疗领域迎来根本性变革。此次大会最引人瞩目的突破，来自新一代联合疗法以及针对早期干预中一直存在的治疗局限性的创新方案。 这场年度大会开设了100余场科学研讨会，展示了诺和诺德、礼来公司、Viking Therapeutics、歌礼制药、Skye Bioscience、Palatin Technologies、Neurogastrx公司、OrsoBio公司、Metsera公司等顶尖制药企业的创新成果。这些成果不仅体现了药物疗效的重大突破，更重塑了这个价值数十亿美元的肥胖症治疗市场。一系列研究表明，肥胖管理已从制药领域的小众方向，发展成为医疗健康与商业领域的核心议题。 诺和诺德的CagriSema：双靶点及多靶点激动剂的主导地位 最具影响力的研究成果集中在双靶点激动剂疗法领域。诺和诺德的每周一次注射剂 CagriSema，通过联合卡格列肽（一种胰岛淀粉样多肽类似物）与司美格鲁肽（一种GLP-1受体激动剂），在大会公布的REDEFINE 5试验中展现出优于单药治疗的疗效。该试验纳入了日本和台湾地区22个研究中心的331名超重或肥胖亚洲受试者，结果显示CagriSema组平均减重18.4%，而司美格鲁肽单药组为11.9%。更值得关注的是，95.4%的CagriSema受试者实现了≥5%的减重，高于司美格鲁肽单药组的78.7%；39.4%的受试者减重≥20%，而单药组仅为18.6%。联合疗法还使腰围减少13.5cm，优于单药组的9.7cm，且安全性与单药治疗相当。 这一进展标志着肥胖症治疗药物领域的重大转变。不同作用机制药物的联合协同疗法已成为新兴标准，其带来的5-7个百分点的体重降幅提升，将显著改善患者预后并重塑市场格局。 诺和诺德口服司美格鲁肽取得新进展 诺和诺德公布了支持口服司美格鲁肽成为重大治疗突破的有力数据。OASIS 4试验结果同步发表于《新英格兰医学杂志》，显示每日一次 25 毫克口服司美格鲁肽的平均减重达14%，而安慰剂组仅为2%。值得注意的是，30%的受试者实现了≥20% 的减重，远高于安慰剂组的3%，其疗效与注射剂型司美格鲁肽相当。口服司美格鲁肽组的身体功能评分显著提高 16 分，安慰剂组仅提高8分，这一核心生活质量指标对药物的实际应用至关重要。 口服剂型与注射剂型疗效相当的突破，从根本上普及了肥胖治疗的可及性。口服给药消除了注射焦虑，提高了依从性，并将适用人群扩大到此前不愿或无法自行注射的患者群体，这是一个庞大的未被满足的肥胖治疗市场。 礼来新型胰岛淀粉样多肽激动剂的潜力 礼来的选择性胰岛淀粉样多肽受体激动剂eloralintide，在肥胖周公布的2期试验结果超出了此前确立的安全性 - 疗效平衡标准。在 48 周的治疗中，eloralintide 的平均减重范围为 9.5%-20.1%（取决于剂量），所有治疗组的疗效均显著优于安慰剂组的0.4%。值得注意的是，2期结果显示其耐受性优于GLP-1类药物，同时保持了具有临床意义的减重效果。礼来计划于2025年12月启动该药物的3期临床试验。 eloralintide独特的作用机制代表了治疗领域的关键多元化发展。随着GLP-1药物供应限制的缓解，这一替代途径将满足大量对肠促胰素激动剂相关胃肠道副作用不耐受的患者需求。 Viking Therapeutics的VK2735双靶点激动剂获突破 Viking Therapeutics公布了其双靶点GLP-1/GIP 受体激动剂VK2735的2期VENTURE试验数据，该药物采用每周皮下注射给药。探索性分析显示，在试验初期确诊为糖尿病前期的受试者中，接受VK2735治疗的患者到第13周时血糖恢复至正常水平的比例达78%，远超安慰剂组29%的血糖正常化比例，两组差异具有显著统计学意义（p值=0.0008）。 该药物在逆转代谢综合征方面同样取得了显著成效：试验初期符合代谢综合征诊断标准的受试者中，68%接受VK2735治疗的患者到第13周已不再满足该病症的诊断条件，而安慰剂组这一比例仅为38%，两组数据差异具有统计学意义（p值=0.02）。此前公布的数据显示，VK2735治疗13周后，平均体重较基线显著下降高达14.7%，且未观察到平台期。值得注意的是，88%的VK2735治疗患者实现了≥10%的减重，而安慰剂组仅为4%，且92%的治疗相关不良反应事件为轻至中度，安全性良好。 歌礼制药肥胖症候选药物研发数据成果显著 歌礼制药在2025年肥胖周公布了其多个肥胖候选药物的喜人研究结果。ASC30（一种每日一次口服 GLP-1R偏向性小分子激动剂）的1b期试验显示，28天后安慰剂校正后的平均减重高达6.5%，最高剂量组的最大减重达9.3%。该药物耐受性良好，仅出现轻至中度胃肠道副作用，无严重不良事件报告。 此外，ASC30的皮下注射剂型展现出超长作用潜力，半衰期支持每月一次治疗和每季度一次维持给药方案。这些剂型的安全性与现有GLP-1R激动剂相当或更优。 新型联合疗法 ASC31（双靶点GLP-1R和GIPR肽激动剂）与 ASC47（靶向脂肪组织的甲状腺激素受体β选择性小分子）的临床前研究显示，在饮食诱导肥胖小鼠中，该联合疗法的减重和减脂效果显著优于替尔泊肽或ASC31单药治疗。同时，该联合疗法还能保留肌肉量，使身体成分更接近健康水平。 这些数据验证了歌礼制药自主研发的人工智能辅助结构型药物发现（AISBDD）和超长作用平台（ULAP）技术，彰显了其管线中口服和注射候选药物的潜力，通过提高疗效、安全性和患者便利性，为慢性体重管理带来突破。歌礼制药致力于推进全球临床开发和战略合作伙伴关系。 Skye Bioscience 预防体重反弹的联合疗法 Skye Bioscience报告聚焦一个关键的未被满足的临床需求：预防GLP-1受体激动剂停药后的体重反弹。其2期CBeyond试验数据显示，尼马昔单抗（一种外周限制性 CB1 抑制剂抗体）联合司美格鲁肽，在治疗后12周内显著抑制了反弹式体重增加，体重反弹率仅为18.1%，而司美格鲁肽单药组为49.8%。 治疗后12周，联合治疗组与安慰剂组相比仍保持统计学显著性差异（p=0.006），而司美格鲁肽单药组则失去统计学显著性（p=0.12），这与 STEP-1试验延伸研究中记录的反弹式体重增加既定趋势一致。在积极治疗阶段，尼马昔单抗联合司美格鲁肽的额外减重达-13.2%，优于司美格鲁肽单药组的-10.25%（p=0.0372），减重效果提升约30%。联合治疗组的腰围减少也更显著，为-11.26cm，而司美格鲁肽单药组为-8.09cm（p=0.0492）。 Palatin Technologies的黑皮质素通路创新 该公司展示了黑皮质素- 4受体（MC4R）激动剂作为肠促胰素类疗法补充机制的临床前及临床数据。其海报展示了口服 MC4R小分子激动剂PL7737，该药物在饮食诱导肥胖小鼠中展现出剂量依赖性减重效果，且未对收缩压产生影响，同时具有良好的药代动力学特征 —— 包括在大鼠体内约50%的口服生物利用度和超过3小时的半衰期。 一项 II 期研究（BMT-801）评估了黑皮质素-4受体激动剂布美诺肽与替尔泊肽联合用于肥胖患者的效果。结果显示，相较于替尔泊肽单药治疗，添加低剂量MC4R激动剂可实现更显著的减重，且耐受性良好，未增加胃肠道副作用。关键的是，在替尔泊肽停药后，使用低剂量MC4R激动剂可维持体重，防止反弹，这一结果与Skye公司在CB1通路中取得的发现具有相似性。目前，PL7737已获得治疗瘦素受体缺乏相关肥胖的孤儿药资格认定，预计于2026年上半年提交新药临床试验申请并启动1期试验。 Neurogastrx针对GLP-1耐受性挑战的解决方案 GLP-1疗法应用中最关键的商业壁垒或许是耐受性问题，Neurogastrx展示了其NG101(metopimazine mesylate)2期研究的概念验证数据。NG101 是一种口服外周限制性多巴胺 D2 受体拮抗剂，用于治疗GLP-1诱导的胃肠道副作用。该研究纳入90名18-55岁受试者，均接受司美格鲁肽治疗，同时分别服用 NG101（20mg，每日两次）或安慰剂。结果显示NG101 使恶心发生率显著降低40%（p=0.0203），呕吐发生率降低67%（p=0.0274），且呕吐发作次数减少56%（p=0.0238）。 胃肠道症状持续时间也大幅改善：NG101 组中恶心呕吐持续超过一天的受试者占比22%，而安慰剂组为51%（p=0.0063）,恶心严重程度降低70%（p=0.0138）。治疗后 12 周，NG101 组受试者的中重度恶心最高评分显著降低31%（p=0.0225）。 这一数据的重要性不言而喻：在因减重启动GLP-1疗法的患者中，仅30% 能坚持治疗满一年，而胃肠道副作用是导致停药的首要原因。 Metsera公司MET-097i Ⅱb期临床试验结果 Metsera公司于2025年肥胖症大会（ObesityWeek 2025）上公布了其减肥候选药物MET-097i的两项Ⅱb期临床试验（VESPER-1试验与 VESPER-3试验）阳性结果。该药物展现出优异的减重效果，与礼来公司的 ZEPBOUND 等主流药物相当。在 VESPER-1试验中，治疗28周时，MET-097i相较于安慰剂的平均减重幅度最高达14.1%，部分受试者减重比例甚至高达26.5%。尽管属于单靶点激动剂药物，其疗效却可与双靶点激动剂疗法相媲美。 MET-097i的突出优势在于其出色的耐受性。VESPER-1试验中，该药物的治疗中断率仅为 2.9%；VESPER-3试验中，最高剂量组的胃肠道副作用发生率极低，恶心发生率为13%、呕吐发生率为11%，腹泻症状也较轻微。相比之下，当前市场主流减肥药物的副作用通常更为明显，常导致患者中断治疗，而MET-097i的耐受性数据颇具竞争力。 这一进展正值辉瑞与诺和诺德对Metsera展开竞购之际，最终辉瑞胜出，彰显了MET-097i的市场潜力。 OrsoBio 用于肥胖的线粒体质子载体疗法 OrsoBio公布了TLC-6740的1期数据，同时启动了新型口服胰岛淀粉样多肽受体激动剂TLC-1180的首次人体试验。初步7周疗效数据显示，低剂量TLC-1180 与司美格鲁肽的载体校正减重效果相近（分别为11%和14%），高剂量 TLC-1180的减重达20%，而 TLC-1180 与司美格鲁肽的联合治疗减重达27%，脂肪量减少67%，且不影响瘦肌肉量-这是与现有疗法相比的关键差异化优势。 2025年肥胖症大会上公布的其他重要研究成果 2025 年肥胖症大会还呈现了多家深耕肥胖症治疗研发领域的制药企业的一系列颇具前景的研究成果，包括Ro、恒瑞医药、Kailera Therapeutics、MetaVia、Veru、Currax Pharmaceuticals、Biomea Fusion 和 Aion Medicines 等。 Ro，这一直面患者的医疗健康企业，提交了八份研究摘要，重点阐述了替尔泊肽、司美格鲁肽等胰高糖素样肽-1类疗法通过远程医疗模式应用的真实世界疗效数据。数据显示，患者减重显著（12个月时高达19.5%），骨关节炎或减重手术后等特定人群的症状也得到改善。该公司还展示了包含大型语言模型分诊工具在内的人工智能技术在提升患者诊疗效率方面的作用。此外，他们探索了 “食物噪音” 等患者体验-这种侵入性的食物相关想法会对生活质量产生负面影响，研究旨在通过捕捉患者的细微感受，进一步完善肥胖症诊疗方案. 恒瑞医药和Kailera Therapeutics公布了新型双靶点GLP-1/GIP受体激动剂HRS9531用于中国肥胖成人的3期GEMINI-1试验结果。该试验证实，这款药物不仅减重效果显著，优于安慰剂，还能改善血压、胰岛素抵抗等多种代谢相关心血管风险因素。Kailera Therapeutics计划开展全球性Ⅲ期临床试验，评估更高剂量和更长治疗周期的效果，以进一步推进该疗法的研发。 MetaVia公布了双靶点激动剂DA-1726的Ⅰ期临床试验数据与临床前研究数据。结果显示，该药物安全性良好，药代动力学特性适宜每周给药一次；同时能显著降低肥胖成人的体重和腰围。临床前啮齿动物研究表明，DA-1726通过增加能量消耗实现减重，降脂效果优于对照药物。 Veru公司在在大会上提交了两份研究摘要，重点介绍了其新一代药物enobosarm-一种选择性雄激素受体调节剂（SARM），其研发目的是在保证瘦肌肉量与身体机能不受影响的前提下，提升胰高糖素样肽-1受体激动剂类药物减重时减少脂肪的针对性。其2b期QUALITY临床试验及延长研究显示，enobosarm 与司美格鲁肽联合治疗可维持患者的瘦肌肉量与身体机能，有望在积极减重阶段实现更多脂肪减少和能量消耗增加。目前相关机构计划开展后续研究，验证enobosarm是否能帮助接受胰高糖素样肽-1受体激动剂治疗的患者突破减重平台期。 Currax Pharmaceuticals重点介绍了其口服非胰高血糖素样肽-1复方疗法CONTRAVE的最新研究成果，研究聚焦于该药物在抑制食欲渴望、提升患者治疗依从性以及在特定人群中的疗效这几个方面。该公司的研究报告指出，其通过改善体重管理中的生理与行为影响因素，为肥胖症治疗增添了新的选择。 2025 年肥胖周的其他重要成果 Biomea Fusion展示了BMF-650和Icovamenib与低剂量司美格鲁肽联合使用的临床前进展，在啮齿动物模型中显示出增强的血糖控制和减重效果。同时，Aion Medicines分享了AM-710的临床前数据-这是一种超长作用GLP-1受体激动剂前药，给药周期可达每3-6个月一次甚至更久，且在动物试验中表现出显著且持久的减重效果，并能为机体带来代谢层面的益处。 这些研究报告共同彰显了肥胖症治疗领域的重大进展，其核心亮点包括新型长效治疗药物、创新远程医疗给药模式以及技术赋能的患者管理方案。这些成果有望在全球范围内重新构建肥胖症的诊疗模式。 肥胖市场的影响与扩张 2025年肥胖周的数据明确了竞争格局的转变。根据DelveInsight的数据，抗肥胖市场预计将从 2024 年的 120 亿美元增长到2034年的约860亿美元（覆盖主要市场：美国、欧盟四国、英国和日本），增幅达 617%。这些市场预测反映了多个增长驱动因素：诊断标准扩大带来的新确诊人群、此前受限或无法获得治疗的患者转向治疗，以及新兴治疗类别突破现有单药治疗的局限性。 尽管诺和诺德的司美格鲁肽和礼来的替尔泊肽仍占据肥胖市场的主导地位，但下一代药物的激增正构建差异化路径。多选择格局的形成使精准医疗成为可能，临床医生可根据疗效目标、耐受性偏好和合并症特征对患者进行分层治疗。这标志着减肥药物市场正从单一疗法主导的模式，逐步迈向个体化治疗方案的成熟阶段。从过往经验来看，这类转型通过提高患者治疗依从性、扩大适应症适用范围，通常能推动整体市场规模增长30%-50%。 总之，大会强调了将肥胖作为慢性疾病治疗的重要性，需通过涵盖基础科学、临床应用和公共政策的多学科方法。主要亮点包括GLP-1激动剂的新数据和新兴口服治疗方案，这些方案显示出显著的减重效果和代谢改善。值得注意的是，会议既指出了当前存在的治疗依从性差、患者就医可及性不足等问题，也分享了多种创新策略，这些策略能够助力患者维持长期治疗效果，并提升肥胖症患者的生活质量。作为一场全球性的专家盛会，2025年肥胖症专题会议推动了行业探讨，助力肥胖症诊疗模式向个体化、以患者为中心的方向转型。 原文出自：ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight 立即扫码加入药事纵横交流群